Phosphodiesterase type 5 inhibitors in the treatmentof symptoms of lower urinary tract and erectile dysfunctionin patients with benign prostatic hyperplasia
Phosphodiesterase type 5 inhibitors (PDE -5 inhibitor) improve significantly the urinary tract symptoms in the men with benign prostatic hyperplasia and are a prospective group of medications for the treatment of patients with acraturesis (lower urinary tract symptoms). Udenafil (Zidena®) - a highly selective PDE -5 inhibitor with proven efficacy in patients with lower urinary tract symptoms with erectile dysfunction, or without it. The medication has an optimal duration of action and a reliable safety profile.